75 岁及以上 2 型糖尿病患者使用 SGLT2 抑制剂的安全性队列研究
本研究基于加拿大不列颠哥伦比亚省行政健康数据库,纳入 2021 年 1 月 1 日至 2023 年 12 月 31 日期间起始使用 SGLT2 抑制剂或 DPP-4 抑制剂的 75 岁及以上 2 型糖尿病患者。比较两组在感染、糖尿病酮症酸中毒、急性肾损伤、跌倒、骨折及全因住院方面的安全性。结果显示 SGLT2 抑制剂起始与急性肾损伤和全因住院风险较低相关,未发现其他结局风险增加。
要点
- SGLT2 抑制剂起始与急性肾损伤风险较低相关(HR 0.76, 95% CI 0.60-0.95)。
- SGLT2 抑制剂起始与全因住院风险较低相关(HR 0.87, 95% CI 0.77-0.98)。
- 糖尿病酮症酸中毒、跌倒、骨折的风险未见差异,但置信区间较宽。
核心结论
- 与 DPP-4 抑制剂起始相比,75 岁及以上 2 型糖尿病患者起始 SGLT2 抑制剂未显示危害风险增加,尽管部分结局估计不精确。
研究设计与样本
- 基于人群的活性对照新使用者队列研究,使用加拿大不列颠哥伦比亚省行政健康数据库。
- 纳入 2021 年 1 月 1 日至 2023 年 12 月 31 日期间起始 SGLT2 抑制剂或 DPP-4 抑制剂的 75 岁及以上 2 型糖尿病患者。
- SGLT2 抑制剂起始者 4997 例(中位年龄 79 岁,37% 为女性),DPP-4 抑制剂起始者 1289 例(中位年龄 82 岁,50% 为女性)。
- 使用倾向评分标准化死亡比加权 Cox 回归估计风险比。
主要发现
- 与 DPP-4 抑制剂起始相比,SGLT2 抑制剂起始与急性肾损伤风险较低相关(HR 0.76, 95% CI 0.60-0.95)。
- 与 DPP-4 抑制剂起始相比,SGLT2 抑制剂起始与全因住院风险较低相关(HR 0.87, 95% CI 0.77-0.98)。
- 感染风险在两组间无差异。
- 糖尿病酮症酸中毒、跌倒、骨折的风险在两组间未观察到差异,但置信区间与获益和危害均相符。
关键数值与推荐
- 主要结局包括感染、糖尿病酮症酸中毒、急性肾损伤、跌倒、骨折和全因住院。
临床怎么用
- 研究结果支持在 75 岁及以上 2 型糖尿病患者中考虑将 SGLT2 抑制剂作为一种治疗选择。
局限性
- 部分结局的估计不精确,置信区间较宽,无法排除获益或危害。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have demonstrated cardiorenal benefits in individuals with type 2 diabetes, but safety data in older adults remain limited. We evaluated the real-world safety of SGLT2is compared with dipeptidyl peptidase 4 inhibitors (DPP-4is) among individuals aged ≥75 years with type 2 diabetes. RESEARCH DESIGN AND METHODS: We conducted a population-based, active-comparator, new-user cohort study using administrative health databases from British Columbia, Canada. We included individuals aged ≥75 years with type 2 diabetes initiating SGLT2is or DPP-4is between 1 January 2021 and 31 December 2023. Primary outcomes were infection, diabetic ketoacidosis, acute kidney injury, fall, fracture, and all-cause hospitalization. Cox regression with propensity score-based standardized mortality ratio weighting was used to estimate hazard ratios (HRs). RESULTS: The study included 4,997 SGLT2i initiators (median age, 79 years; 37% women) and 1,289 DPP-4i initiators (median age, 82 years; 50% women). Compared with DPP-4i initiation, SGLT2i initiation was associated with lower risks of acute kidney injury (HR 0.76, 95% CI 0.60-0.95) and all-cause hospitalization (HR 0.87, 95% CI 0.77-0.98), with no difference in risk of infection. No differences were observed in risk of diabetic ketoacidosis, falls, or fractures, although CIs were compatible with both benefit and harm. CONCLUSIONS: In individuals aged ≥75 years with type 2 diabetes, SGLT2i initiation was not associated with increased risk of harm compared with DPP-4i initiation, although estimates were imprecise for some outcomes. These findings may support consideration of SGLT2is as a treatment option in this population.
引用
- Harbi, Nesrallah, Carney, et al. Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults With Type 2 Diabetes: A Cohort Study. Diabetes Care. 2026. PMID: 42937517. doi:10.2337/dc26-1316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。